<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03599869</url>
  </required_header>
  <id_info>
    <org_study_id>PSS2017/ELABEST-BONMATI/VS</org_study_id>
    <nct_id>NCT03599869</nct_id>
  </id_info>
  <brief_title>Management of Mixed-Phenotype Acute Leukemia in the East of France</brief_title>
  <acronym>ELABEST</acronym>
  <official_title>Management of Mixed-Phenotype Acute Leukemia in the East of France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical presentation and management of Mixed-Phenotype Acute leukemia (MPAL) is
      heterogeneous. This descriptive observationnal study aims to review MPAL cases in the East of
      France based on a 10-year multicentre retrospective collection.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">September 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Age of the patients when diagnosed with MPAL</measure>
    <time_frame>At inclusion (Day 0)</time_frame>
    <description>Age in years</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sex of the patients when diagnosed with MPAL</measure>
    <time_frame>At inclusion (Day 0)</time_frame>
    <description>Male or female</description>
  </primary_outcome>
  <primary_outcome>
    <measure>City of the hematology unit in charge of each patient for the treatment of MPAL</measure>
    <time_frame>At inclusion (Day 0)</time_frame>
    <description>Nancy, Metz-Thionville, Reims, Strasbourg, Mulhouse, Dijon or Besançon</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MPAL rate in the each hematology unit</measure>
    <time_frame>10 years (01/01/2008-01/01/2018)</time_frame>
    <description>Rate of MPAL out of the total number of patients diagnosed with acute leukemia in each hematology unit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Date of MPAL diagnosis for each patient</measure>
    <time_frame>At inclusion (Day 0)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Type of MPAL for each patient</measure>
    <time_frame>At inclusion (Day 0)</time_frame>
    <description>De novo MPAL or secondary to myelodysplasia MPAL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of blood blasts for each patient at diagnosis of MPAL</measure>
    <time_frame>At inclusion (D0)</time_frame>
    <description>On the first blood sample analyzed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of medullar blasts for each patient at diagnosis of MPAL</measure>
    <time_frame>At inclusion (Day 0)</time_frame>
    <description>On the first bone marrow sample analyzed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytologic characteristics: type of myeloid markers at diagnosis for each patient</measure>
    <time_frame>At inclusion (Day 0)</time_frame>
    <description>Presence or not of myeloid markers generally sought in the diagnosis of acute leukaemias</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytologic characteristics: type of B lymphoid markers at diagnosis for each patient</measure>
    <time_frame>At inclusion (Day 0)</time_frame>
    <description>Presence or not of B lymphoid markers generally sought in the diagnosis of acute leukaemias</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytologic characteristics: type of T lymphoid markers</measure>
    <time_frame>At inclusion (D0)</time_frame>
    <description>Presence or not of T lymphoid markers generally sought in the diagnosis of acute leukemias</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medullar MPO positivity percentage at diagnosis for each patient</measure>
    <time_frame>At inclusion (Day 0)</time_frame>
    <description>If performed on the bone marrow sample used to confirm the diagnosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genetic characteristics on the caryotype at diagnosis for each patient</measure>
    <time_frame>At inclusion (Day 0)</time_frame>
    <description>Presence or not of caryotypic abnormalities generally sought in the diagnosis of acute leukemias</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genetic characteristics on molecular biology analysis at diagnosis for each patient</measure>
    <time_frame>At inclusion (D0)</time_frame>
    <description>Presence or not of molecular biology abnormalities generally sought in the diagnosis of acute leukemias</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Classification of biphenotypic acute leukemia (BAL) according to the EGIL 1998 criterias at diagnosis</measure>
    <time_frame>At inclusion (Day 0)</time_frame>
    <description>BAL or not</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Classification of MPAL according to the WHO 2008 criterias at diagnosis</measure>
    <time_frame>At inclusion (Day 0)</time_frame>
    <description>MPAL or not</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Type of treatments and dates of the first day of every treatment line for each patient</measure>
    <time_frame>10 years (01/01/2008-01/01/2018)</time_frame>
    <description>Myeloid or lymphoid chemotherapy regimen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medullar response for every treatments line for each patient</measure>
    <time_frame>10 years (01/01/2008-01/01/2018)</time_frame>
    <description>Complete cytological and molecular response or treatment failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment including allogenic hematopoietic stem cells transplant (HSCT) (yes or no) with type of conditionning regimen for each patient</measure>
    <time_frame>10 years (01/01/2008-01/01/2018)</time_frame>
    <description>High-dose, reduced-intensity or nonmyeloablative conditioning regimens with or without total body irradiation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HSCT complicated with acute and/or chronic graft-versus-host disease with severity grade and treatments for each patient</measure>
    <time_frame>10 years (01/01/2008-01/01/2018)</time_frame>
    <description>Diagnosis of GVHD according to Filipovich criterias (BMT 2005); Severity grade according to Seattle criterias; Type of treatments: steroids, other immunosuppressive agents, extracorporeal photopheresis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Date of every relapse for each patient</measure>
    <time_frame>10 years (01/01/2008-01/01/2018)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Date of death if occured</measure>
    <time_frame>10 years (01/01/2008-01/01/2018)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause of death</measure>
    <time_frame>10 years (01/01/2008-01/01/2018)</time_frame>
    <description>Secondary to leukemia, treatment or other cause</description>
  </secondary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Mixed Phenotype Acute Leukemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients from one of the following 7 hospitals : Nancy, Metz-Thionville, Reims,
        Strasbourg, Mulhouse, Dijon, Besançon
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients over 18 years of age

          -  Diagnosis of biphenotypic acute leukemia or mixed-phenotype acute leukemia between
             2008 and 2018
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 22, 2018</study_first_submitted>
  <study_first_submitted_qc>July 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>July 24, 2018</last_update_submitted>
  <last_update_submitted_qc>July 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

